Patient demographics.
| Characteristics | PsA, n = 140 | Psoriasis, n = 51 | FMS, n = 51 | p |
|---|---|---|---|---|
| Sex, M/F | 70/70 | 23/28 | 4/47 | < 0.0001 |
| Age, yrs | 48 (40–58) | 51 (44–57) | 50 (42–57) | ns |
| Disease duration, yrs* | 5.6 (1–8) | 12 (6.0–23) | 3.5 (2–10) | < 0.0001 |
| BMI, kg/m2 | 25.6 (22.0–29.1) | 27.1 (24.3–30.4) | 23.4 (21.5–24.7) | 0.001 |
| Comorbidities, n (%)† | ||||
| Cardiovascular | 30 (21.43) | 15 (29.41) | 11 (21.57) | ns |
| Metabolic, nutrition | 18 (12.86) | 7 (13.75) | 5 (9.8) | ns |
| Endocrine | 14 (10) | 4 (7.84) | 8 (15.69) | ns |
| DAS28 | 3.05 (2.29–4.06) | 2.30 (1.67–2.84) | 2.49 (2.07–4.02) | < 0.0001 |
| ESR, mm/h | 12.0 (6.0–22.0) | 10.0 (6.0–14.0) | 7.0 (5.0–14.2) | ns |
| CRP, mg/dl | 0.30 (0.10–0.90) | 0.30 (0.15–0.59) | 0.20 (0.10–0.30) | ns |
| Smoking, n (%) | 32 (23) | 14 (27) | 17 (33) | ns |
| Alcohol, n (%) | 63 (45) | 15 (29) | 19 (37) | ns |
| Use of pain medications, n (%) | 22 (15.71) | 0 | 6 (11.76) | < 0.05 |
Continuous variables are reported as median and interquartile range.
↵* Since symptoms onset.
↵† Only comorbidities present in > 3% of patients are reported. BMI: body mass index; CRP: C-reactive protein; DAS28: 28-joint count Disease Activity Score; ESR: erythrocyte sedimentation rate; FMS: fibromyalgia syndrome; ns: not significant; PsA: psoriatic arthritis.